Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | FGFR3 |
Variant | A265T |
Impact List | missense |
Protein Effect | no effect - predicted |
Gene Variant Descriptions | FGFR3 A265T lies within Ig-like C2-type domain 3 of the Fgfr3 protein (UniProt.org). A265T results in proliferation similar to wild-type Fgfr3 in a competition assay and transformation activity similar to wild-type Fgfr3 in cultured cells (PMID: 34272467), and therefore, is predicted to have no effect on Fgfr3 protein function. |
Associated Drug Resistance | |
Category Variants Paths |
FGFR3 mutant FGFR3 A265T |
Transcript | NM_000142.5 |
gDNA | chr4:g.1801888G>A |
cDNA | c.793G>A |
Protein | p.A265T |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
NM_001163213.1 | chr4:g.1801888G>A | c.793G>A | p.A265T | RefSeq | GRCh38/hg38 |
NM_001354809.1 | chr4:g.1801888G>A | c.793G>A | p.A265T | RefSeq | GRCh38/hg38 |
NM_001354810.1 | chr4:g.1801888G>A | c.793G>A | p.A265T | RefSeq | GRCh38/hg38 |
XM_047449820.1 | chr4:g.1801888G>A | c.793G>A | p.A265T | RefSeq | GRCh38/hg38 |
NM_022965.4 | chr4:g.1801888G>A | c.793G>A | p.A265T | RefSeq | GRCh38/hg38 |
XM_006713871.1 | chr4:g.1801888G>A | c.793G>A | p.A265T | RefSeq | GRCh38/hg38 |
XM_006713870.2 | chr4:g.1801888G>A | c.793G>A | p.A265T | RefSeq | GRCh38/hg38 |
NM_000142.5 | chr4:g.1801888G>A | c.793G>A | p.A265T | RefSeq | GRCh38/hg38 |
NM_001163213.2 | chr4:g.1801888G>A | c.793G>A | p.A265T | RefSeq | GRCh38/hg38 |
XM_006713868.2 | chr4:g.1801888G>A | c.793G>A | p.A265T | RefSeq | GRCh38/hg38 |
XM_011513420.2 | chr4:g.1801888G>A | c.793G>A | p.A265T | RefSeq | GRCh38/hg38 |
XM_006713873.1 | chr4:g.1801888G>A | c.793G>A | p.A265T | RefSeq | GRCh38/hg38 |
XM_011513420.1 | chr4:g.1801888G>A | c.793G>A | p.A265T | RefSeq | GRCh38/hg38 |
NM_000142.4 | chr4:g.1801888G>A | c.793G>A | p.A265T | RefSeq | GRCh38/hg38 |
XM_006713871.2 | chr4:g.1801888G>A | c.793G>A | p.A265T | RefSeq | GRCh38/hg38 |
XM_006713868.1 | chr4:g.1801888G>A | c.793G>A | p.A265T | RefSeq | GRCh38/hg38 |
XM_047449824.1 | chr4:g.1801888G>A | c.793G>A | p.A265T | RefSeq | GRCh38/hg38 |
XM_011513422.1 | chr4:g.1801888G>A | c.793G>A | p.A265T | RefSeq | GRCh38/hg38 |
XM_047449822.1 | chr4:g.1801888G>A | c.793G>A | p.A265T | RefSeq | GRCh38/hg38 |
NM_001354809.2 | chr4:g.1801888G>A | c.793G>A | p.A265T | RefSeq | GRCh38/hg38 |
XM_047449821.1 | chr4:g.1801888G>A | c.793G>A | p.A265T | RefSeq | GRCh38/hg38 |
XM_011513422.2 | chr4:g.1801888G>A | c.793G>A | p.A265T | RefSeq | GRCh38/hg38 |
XM_047449823.1 | chr4:g.1801888G>A | c.793G>A | p.A265T | RefSeq | GRCh38/hg38 |
XM_006713869.1 | chr4:g.1801888G>A | c.793G>A | p.A265T | RefSeq | GRCh38/hg38 |
XM_006713873.2 | chr4:g.1801888G>A | c.793G>A | p.A265T | RefSeq | GRCh38/hg38 |
XM_006713870.1 | chr4:g.1801888G>A | c.793G>A | p.A265T | RefSeq | GRCh38/hg38 |
XM_006713869.2 | chr4:g.1801888G>A | c.793G>A | p.A265T | RefSeq | GRCh38/hg38 |
NM_001354810.2 | chr4:g.1801888G>A | c.793G>A | p.A265T | RefSeq | GRCh38/hg38 |
NM_022965.3 | chr4:g.1801888G>A | c.793G>A | p.A265T | RefSeq | GRCh38/hg38 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|